tiprankstipranks
Jubilant Pharmova Limited (IN:JUBLPHARMA)
:JUBLPHARMA
India Market
JUBLPHARMA
Jubilant Pharmova Limited
RESEARCH TOOLSreports
Want to see IN:JUBLPHARMA full AI Analyst Report?

Jubilant Pharmova Limited (JUBLPHARMA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

JUBLPHARMA Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Jubilant
Pharmova Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JUBLPHARMA Stock 12 Month Forecast

There Are No Analyst Ratings for IN:JUBLPHARMA In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

JUBLPHARMA Financial Forecast

JUBLPHARMA Earnings Forecast

Next quarter’s earnings estimate for JUBLPHARMA is ₹5.80 with a range of ₹5.80 to ₹5.80. The previous quarter’s EPS was ₹3.50. JUBLPHARMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year JUBLPHARMA has Performed in-line its overall industry.
Next quarter’s earnings estimate for JUBLPHARMA is ₹5.80 with a range of ₹5.80 to ₹5.80. The previous quarter’s EPS was ₹3.50. JUBLPHARMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year JUBLPHARMA has Performed in-line its overall industry.

JUBLPHARMA Sales Forecast

Next quarter’s sales forecast for JUBLPHARMA is ₹22.30B with a range of ₹22.30B to ₹22.30B. The previous quarter’s sales results were ₹22.29B. JUBLPHARMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year JUBLPHARMA has Performed in-line its overall industry.
Next quarter’s sales forecast for JUBLPHARMA is ₹22.30B with a range of ₹22.30B to ₹22.30B. The previous quarter’s sales results were ₹22.29B. JUBLPHARMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year JUBLPHARMA has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
ICICI Securities Analyst forecast on IN:JUBLPHARMA
Unknown Analyst
ICICI Securities
Not Ranked
ICICI Securities
₹1,310
Buy
36.17%
Upside
Reiterated
02/08/26
ICICI Securities Reaffirms Their Buy Rating on Jubilant Pharmova Limited (JUBLPHARMA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
ICICI Securities Analyst forecast on IN:JUBLPHARMA
Unknown Analyst
ICICI Securities
Not Ranked
ICICI Securities
₹1,310
Buy
36.17%
Upside
Reiterated
02/08/26
ICICI Securities Reaffirms Their Buy Rating on Jubilant Pharmova Limited (JUBLPHARMA)
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

JUBLPHARMA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
0
In the current month, JUBLPHARMA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. JUBLPHARMA average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

JUBLPHARMA Stock Forecast FAQ

What is IN:JUBLPHARMA’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:JUBLPHARMA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:JUBLPHARMA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Jubilant Pharmova Limited a Buy, Sell or Hold?
      Currently, no data Available
      What is Jubilant Pharmova Limited’s share price target?
      Currently, no data Available
      What do analysts say about Jubilant Pharmova Limited?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Jubilant Pharmova Limited?
      To buy shares of IN:JUBLPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.